Xeris hosts webinar on XP-8121 once-weekly subcutaneous levothyroxine
Xeris is hosting a webinar detailing its development program for XP-8121, an investigational once-weekly subcutaneous levothyroxine for hypothyroidism.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.